Pharmacological Effects of Gastric Inhibitory Polypeptide, Cholecystokinin, and Somatostatin on the Serum Levels of Cationic Trypsin-Like Immunoreactivity in Man

Abstract

In six healthy volunteers there were no significant changes during a 300-min control period, whereas gastric inhibitory polypeptide in pharmacological doses first caused a transient and non-significant decrease and then a significant increase in the serum cationic trypsin-like immunoreactivity (CTLI). In another two groups of six healthy subjects, pharmacological doses of cholecystokinin elicited a non-significant increase, whereas somatostatin in pharmacological doses first caused a significant decrease and then a rebound effect with significantly higher levels of serum CTLI.

Key Words:

• Cationic trypsin
• cholecystokinin
• gastric inhibitory polypeptide
• radioimmunoassay
• somatostatin